Immunome (IMNM)
(Delayed Data from NSDQ)
$13.82 USD
+0.09 (0.66%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $13.82 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Balance Sheet
Fiscal Year End for Immunome, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 138 | 20 | 49 | 40 | 3 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 7 | 2 | 7 | 3 | 1 |
Total Current Assets | 145 | 23 | 57 | 43 | 3 |
Net Property & Equipment | 2 | 1 | 1 | 2 | 2 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 149 | 24 | 58 | 45 | 5 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 3 | 2 | 3 | 1 | 1 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 8 | 5 | 7 | 1 | 1 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 10 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 22 | 7 | 10 | 3 | 2 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 5 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 1 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 29 | 7 | 10 | 3 | 2 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 39 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 343 | 133 | 127 | 96 | 1 |
Retained Earnings | -223 | -116 | -79 | -54 | -37 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 120 | 17 | 48 | 41 | 3 |
Total Liabilities & Shareholder's Equity | 149 | 24 | 58 | 45 | 5 |
Total Common Equity | 120 | 17 | 48 | 41 | -36 |
Shares Outstanding | 43.20 | 12.10 | 12.10 | 10.50 | NA |
Book Value Per Share | 2.78 | 1.38 | 3.98 | 3.94 | 0.00 |
Fiscal Year End for Immunome, Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 138 | 91 | 38 | 44 |
Receivables | NA | 0 | 0 | 0 | 0 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 7 | 1 | 1 | 2 |
Total Current Assets | NA | 145 | 91 | 40 | 47 |
Net Property & Equipment | NA | 2 | 1 | 1 | 1 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 0 | 0 | 0 | 0 |
Total Assets | NA | 149 | 93 | 41 | 48 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 3 | 3 | 4 | 3 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 8 | 3 | 5 | 3 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 10 | 17 | 18 | 18 |
Total Current Liabilities | NA | 22 | 23 | 26 | 25 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 5 | 3 | 6 | 9 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 61 | 0 | 0 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 29 | 87 | 32 | 34 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 343 | 136 | 135 | 134 |
Retained Earnings | NA | -223 | -130 | -126 | -120 |
Other Equity | NA | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 120 | 6 | 9 | 14 |
Total Liabilities & Shareholder's Equity | NA | 149 | 93 | 41 | 48 |
Total Common Equity | 0 | 120 | 6 | 9 | 14 |
Shares Outstanding | 59.60 | 43.20 | 12.20 | 12.20 | 12.20 |
Book Value Per Share | 0.00 | 2.78 | 0.50 | 0.77 | 1.14 |